Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2023 –2030 | |
|
|
USD 40,763.40 Million |
| USD 70,564.48 Million | |
| % | |
|
Global Inactivated Vaccines Market, By Product (Viral, Bacterial, others), Route of Administration (Oral, Subcutaneous, Others), Method of Inactivation (Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
The wide introduction of new inactivated vaccines after completion of clinical studies are anticipated to increase the growth of the market during the forecast period. Increasing cases of infectious diseases boosts the inactivated vaccines market. The increasing frequency of several viral and bacterial infections globally has boosted demand for inactivated vaccines that will drive the market forward. Annual influenza outbreaks, for one, were expected to cause 3 to 5 million cases of serious influenza and 290,000 to 650,000 fatalities in 2018, according to the World Health Organization (WHO) report.
Data Bridge Market Research analyses a growth rate in the inactivated vaccines market in the forecast period 2023-2030. The expected CAGR of inactivated vaccines market is tend to be around 7.10% in the mentioned forecast period. The market is valued at USD 40,763.4 million in 2022, and it will grow upto USD 70,564.48 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Viral, Bacterial, others), Route of Administration (Oral, Subcutaneous, Others), Method of Inactivation (Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GSK plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Bharat Biotech (India), Serum Institute of India Pvt. Ltd (India), Valneva SE (France), Bavarian Nordic (Denmark), INOVIO Pharmaceuticals (U.S.), Novavax (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Mitsubishi Chemical Group Corporation (Japan)
|
|
Market Opportunities
|
|
Market Definition
Inactivated vaccines are grown in controlled culture conditions and are killed to decrease their infectivity. Inactivated vaccines are found to be not that much effective compared tolive-attenuated vaccines. Multiple booster shots and immunologic adjuvants are essential to provide an effective immune response against the diseases. Inactivated vaccines include whole-cell inactivated vaccines such as polio, hepatitis A, and rabies vaccines, subunit vaccines such as influenza and pneumococcal vaccines, toxoids such as diphtheria and tetanus toxoid, and recombinant vaccines such as hepatitis B, human papillomavirus [HPV], and influenza
Drivers
The wide introduction of new inactivated vaccines after completion of clinical studies are anticipated to increase the growth of the inactivated vaccines market during the forecast period. For instance, Merck’s investigational inactivated varicella zoster virus vaccine (V212) specified that a decrease in the occurrence of herpes zoster case by an estimated 64% in immunocompromised subjects in the first phase 3 trial in 2017. Clinical studies also showed that V212 lessens the incidence of herpes zoster pain by about 69.5%. Furthermore, V212 showed 83.7% reduction in the prevalence of post herpetic neuralgia. Furthermore, Bharat Biotech launched JENVAC vaccine to offer long-term protection and immunogenicity against Japanese encephalitis in 2013. The primary benefit of this novel fully indigenous inactivated vaccine is that it can be administered during disease epidemics, since it is an inactivated vaccine and is highly purified. Thus, this boosts the market growth.
Opportunities
Increasing occurrence of numerous viral and bacterial diseases globally have increased the demand for inactivated vaccines, which in turn will boost the market growth. For instance, as per the records of the World Health Organization (WHO) report in 2018, annual epidemics because of influenza were expected to result in about 3 to 5 million cases of extreme illness and around 290,000 to 650,000 deaths. Furthermore, WHO 2018 report also signified that about 21 million cases and 222,000 typhoid-related deaths occur annually globally. Thus, this factor boost the market growth.
The increasing government support towards the growth of healthcare sector is most likely to increase the growth of inactivated vaccine market revenue in this region. For instance, the U.S. Department of Health and Human Services shifted funds of about US$ 81 million from other projects to continue developing vaccines to fight against Zika virus in 2016. Thus, this factor in creases the market growth.
Restraints/Challenges
The increasing expenditure associated with the manufacturing and delivering the vaccines hamper the market growth. These vaccines require immense expenditure and the cost is also high and thus people in the major developing and underdeveloped countries, cannot adopt for the vaccines. This impedes the market growth.
This inactivated vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the inactivated vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The inactivated vaccines market is segmented on the basis of product, route of administration, method of activation, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
Route of Administration
Method of Activation
End User
Distribution Channel
The inactivated vaccines market is analyzed and market size insights and trends are provided by product, route of administration, method of activation, end-users and distribution channel as referenced above.
The major countries covered in the inactivated vaccines market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for inactivated vaccines market throughout the forecasted period because of the focus of major market players on novel technology or formulation of existing drugs. A rise in infectious illness and viral infection instances, upgraded health service, and an improvement of health consciousness among private agencies and government are the major drivers boosting the market growth in this region throughout the forecast period 2023-2030.
Asia-Pacific dominates the market because of the high incidence cases of infectious diseases and number of generic drugs. Rapidly growing population combined with urbanization, technical advances and infrastructural developments in the medical sector, an uptick in government expenditure to increase the immunization programs, and sprouting health awareness through NGOs' campaigns are some of the forces prompting the regional market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The inactivated vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to inactivated vaccines market
Key players operating in the inactivated vaccines market include:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.